1. Home
  2. CRSP vs ENIC Comparison

CRSP vs ENIC Comparison

Compare CRSP & ENIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • ENIC
  • Stock Information
  • Founded
  • CRSP 2013
  • ENIC 2016
  • Country
  • CRSP Switzerland
  • ENIC Chile
  • Employees
  • CRSP N/A
  • ENIC N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • ENIC Electric Utilities: Central
  • Sector
  • CRSP Health Care
  • ENIC Utilities
  • Exchange
  • CRSP Nasdaq
  • ENIC Nasdaq
  • Market Cap
  • CRSP 4.9B
  • ENIC 5.1B
  • IPO Year
  • CRSP 2016
  • ENIC N/A
  • Fundamental
  • Price
  • CRSP $59.62
  • ENIC $3.87
  • Analyst Decision
  • CRSP Buy
  • ENIC Hold
  • Analyst Count
  • CRSP 16
  • ENIC 2
  • Target Price
  • CRSP $72.27
  • ENIC $3.90
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • ENIC 553.1K
  • Earning Date
  • CRSP 11-04-2025
  • ENIC 10-28-2025
  • Dividend Yield
  • CRSP N/A
  • ENIC 4.91%
  • EPS Growth
  • CRSP N/A
  • ENIC N/A
  • EPS
  • CRSP N/A
  • ENIC 0.00
  • Revenue
  • CRSP $38,050,000.00
  • ENIC $4,040,237,917.00
  • Revenue This Year
  • CRSP N/A
  • ENIC $111,648.61
  • Revenue Next Year
  • CRSP $348.18
  • ENIC N/A
  • P/E Ratio
  • CRSP N/A
  • ENIC $39.35
  • Revenue Growth
  • CRSP N/A
  • ENIC N/A
  • 52 Week Low
  • CRSP $30.04
  • ENIC $2.59
  • 52 Week High
  • CRSP $71.13
  • ENIC $4.05
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 60.26
  • ENIC 71.83
  • Support Level
  • CRSP $51.63
  • ENIC $3.59
  • Resistance Level
  • CRSP $62.08
  • ENIC $3.89
  • Average True Range (ATR)
  • CRSP 2.52
  • ENIC 0.09
  • MACD
  • CRSP 0.84
  • ENIC 0.03
  • Stochastic Oscillator
  • CRSP 78.13
  • ENIC 95.56

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About ENIC Enel Chile S.A. (Each representing 50 shares of)

Enel Chile SA is an electricity utility company, which through its subsidiaries and affiliates is engaged in the generation, transmission and distribution of electricity businesses in Chile. It operates through two segments including Generation Business and Distribution and Network Business. The Generation Business Segment is comprised of a group of electricity companies that own electricity generating plants, whose energy is transmitted and distributed to end customers. The Distribution and Network Reportable Segment is comprised of a group of electricity companies operating under a public utility concession.

Share on Social Networks: